2013.
Under the programme initiated 31 October 2013, Novo Nordisk will repurchase B shares for an amount up to DKK 2.8 billion in the period from 31 October 2013 to 28 January
2014.
Since the announcement as of 23 December 2013, the following transactions have been made under the programme:
2 January 2014 265,000 200.77 53,204,792
3 January 2014 240,000 203.66 48,877,656
6 January 2014 275,000 205.08 56,396,945
7 January 2014 265,000 205.43 54,439,613
8 January 2014 265,000 207.51 54,990,044
9 January 2014 265,000 209.64 55,553,593
10 January 2014 265,000 210.20 55,702,417
With the transactions stated above, Novo Nordisk owns a total of 104,692,025 treasury shares, corresponding to 3.8% of the share capital. The total amount of shares in the company is 2,750,000,000 including treasury shares.
Novo Nordisk A/SInvestor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 2 / 2014
Page 2 of 2
Novo Nordisk expects to repurchase B shares for an amount up to DKK 14.0 billion during a 12-month period beginning 31 January 2013. As of 10 January 2014, Novo Nordisk has repurchased a total of 69,420,270 B shares equal to a transaction value of DKK
13,366,985,811.
Novo Nordisk is a global healthcare company with 90 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy. Headquartered in Denmark, Novo Nordisk employs approximately 37,000 employees in 75 countries, and markets its products in more than 180 countries. Novo Nordisk's B
shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock
Exchange (NVO). For more information, visit novonordisk.com.
Further information Media: Anne Margrethe Hauge Ken Inchausti (US) | +45 4442 3450 +1 609 514 8316 | amhg@novonordisk.com kiau@novonordisk.com |
Investors: Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com |
Frank Daniel Mersebach Lars Borup Jacobsen Daniel Bohsen Jannick Lindegaard (US) | +45 3079 0604 +45 3075 3479 +45 3079 6376 +1 609 235 8567 | fdni@novonordisk.com lbpj@novonordisk.com dabo@novonordisk.com jlis@novonordisk.com |
Investor Relations
Novo Allé
2880 Bagsværd
Denmark
Telephone:
+45 4444 8888
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
Company announcement No 2 / 2014
distributed by
|